Claims for Patent: 4,393,040

Summary for Patent: 4,393,040

Title:	In-vitro diagnostic method for detection of acetylsalicylic acid ingestion
Abstract:	An in-vitro diagnostic method is provided for detecting acetylsalicylic acid ingestion by a patient by utilizing radioimmunoassay procedure. The method comprises the steps of: derivatizing acetylsalicylic acid with a protein moiety being effected in a molar ratio of about one mole of protein to at least thirty moles of acetylsalicylic acid; coupling the acetylsalicylic acid derivatized protein with a water insoluble solid matrix by binding with a selected chemical agent; obtaining a sample of patient serum; freeze drying the serum including any antibodies specific to acetylsalicylic acid to concentrate the serum to a solid phase; diluting the freeze dried serum to from about 100 to about 1,000 times its original concentration; incubating the solid matrix coupled with the acetylsalicylic acid derivatized protein with the concentrated serum for a sufficient period of time to allow any antibodies specific to acetylsalicylic acid to attach to the solid matrix coupled with the acetylsalicylic acid derivatized protein, the incubation occurring for at least 24 hours at a temperature range of from about 4.degree. C. to about 42.degree. C.; thereafter, incubating the solid phase bound with specific antibodies present with radioactively labelled antibodies specific to acetylsalicylic acid derivatized protein obtained from a test animal for a sufficient period of time to allow binding between the labelled antibodies and the matrix; separating the mixture into distinct liquid and solid phases; and measuring the radiation emitted from at least one of the separated phases.
Inventor(s):	Lopapa; Alberto F. (Los Angeles, CA), Hall; Theodore D. (Los Angeles, CA)
Assignee:	Lopapa Institute, Inc. (Los Angeles, CA)
Application Number:	06/246,993
Patent Claims:	1. An in-vitro diagnostic method for detecting acetylsalicylic acid ingestion by a patient by utilizing radioimmunoassay procedure, the method comprising the steps of: (a) derivatizing acetylsalicylic acid with a protein moiety, said derivatizing procedure being effected in a molar ratio of about 1 mole of protein to at least 30 moles of acetylsalicylic acid; (b) coupling the acetylsalicylic acid derivatized protein obtained from step (a) with a water insoluble solid matrix, said coupling being effected with a coupling agent having a reactive group selected from the group consisting of amino groups, hydroxyl groups, nitro groups, halo groups, amido groups, carboxylic groups and mixtures thereof; (c) obtaining a sample of serum from a patient suspected of having ingested acetylsalicylic acid; (d) lyophilizing said serum including any antibodies specific to acetylsalicylic acid to concentrate said serum to a solid phase; (e) diluting said lyophilized serum to from about 100 to about 1,000 times the serum's original concentration; (f) incubating said solid matrix coupled with the acetylsalicylic acid derivatized protein with said concentrated serum for a sufficient period of time to allow any antibodies specific to acetylsalicylic acid to attach to said solid matrix coupled with the acetylsalicylic acid derivatized protein, said incubation occurring for a period of at least 24 hours at a temperature of from about 4.degree. C. to about 42.degree. C.; (g) thereafter, incubating said solid matrix bound with specific antibodies present with radioactively labelled antibodies specific to acetylsalicylic acid derivatized protein obtained from a test animal for a sufficient period of time to allow binding between said labelled antibodies and said solid matrix obtained from step (f); (h) separating the solid matrix from the liquid phase; (i) and measuring radiation emitted from at least one of the separated phases. 2. The method as defined in claim 1 wherein the step of derivatizing is effected in a molar ratio of about 1 mole of protein to from about 30 to about 45 moles of acetylsalicylic acid. 3. The method as defined in claim 1 wherein said protein moiety has a molecular weight of greater than about 6,000. 4. The method as defined in claim 1 wherein said protein moiety is selected from the group consisting of human serum albumin, human immunoglobulins, bovine serum albumin, bovine immunoglobulins, keyhole limpet, limulus hemocyanin and mixtures thereof. 5. The method as defined in claim 1 wherein said step of incubating said concentrated serum with said coated solid matrix obtained from step (b) occurs for a period of time from about 24 hours to about 100 hours at a temperature range of from 4.degree. C. to about 42.degree. C. 6. The method as defined in claim 1 wherein said radioactively labelled antibodies specific to acetylsalicylic acid derivatized protein is prepared by immunizing said test animal with repeated sub-cutaneous injections of acetylsalicylic acid derivatized protein mixed with adjuvant. 7. The method as defined in claim 6 wherein said adjuvant is Freund's mineral oil suspension. 8. The method as defined in claim 1 wherein said radioactively labelled antibodies specific to acetylsalicylic acid derivatized protein are labelled with radioactive isotopes of iodine.

Details for Patent 4,393,040

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942		2040-01-28
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954		2040-01-28
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976		2040-01-28
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	08/15/1978		2040-01-28